Velika Britanija -
engleski -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 10mg modified-release tablets
sigma pharmaceuticals plc - alfuzosin hydrochloride - modified-release tablet - 10mg
Velika Britanija -
engleski -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 10mg modified-release tablets
mawdsley-brooks & company ltd - alfuzosin hydrochloride - modified-release tablet - 10mg
Velika Britanija -
engleski -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 10mg modified-release tablets
de pharmaceuticals - alfuzosin hydrochloride - modified-release tablet - 10mg
Velika Britanija -
engleski -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 10mg modified-release tablets
actavis uk ltd - alfuzosin hydrochloride - modified-release tablet - 10mg
Velika Britanija -
engleski -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 10mg/5ml oral suspension
special order - alfuzosin hydrochloride - oral suspension - 2mg/1ml
Australija -
engleski -
Department of Health (Therapeutic Goods Administration)
avodart dutasteride 500 microgram soft capsule blister pack
glaxosmithkline australia pty ltd - dutasteride, quantity: 500 microgram - capsule, soft - excipient ingredients: titanium dioxide; mono- and di- glycerides; lecithin; iron oxide yellow; butylated hydroxytoluene; medium chain triglycerides; gelatin; glycerol - avodart is indicated for use as monotherapy for the management of symptomatic benign prostatic hyperplasia (bph) or as combination therapy with an alpha blocker which is approved for use in bph and which has been dose titrated in accordance with the relevant recommendations in the product information for that alpha blocker.
Australija -
engleski -
Department of Health (Therapeutic Goods Administration)
xatral sr alfuzosin 10mg (as hydrochloride) tablet blister pack
sanofi-aventis australia pty ltd - alfuzosin hydrochloride, quantity: 10 mg - tablet, modified release - excipient ingredients: magnesium stearate; ethylcellulose; microcrystalline cellulose; iron oxide yellow; silicon dioxide; mannitol; hypromellose; hydrogenated castor oil; povidone - indicated for the treatment of the functional symptoms of benign prostatic hyperplasia.
Velika Britanija -
engleski -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 2.5mg tablets
medihealth (northern) ltd - alfuzosin hydrochloride - oral tablet - 2.5mg
Kenija -
engleski -
Pharmacy and Poisons Board
zatral er 10mg tabs tablet
alfuzosin hcl bp 10mg - tablet - 10mg tbs - alfuzosin
Irska -
engleski -
HPRA (Health Products Regulatory Authority)
alfuzosin winthrop 10mg prolonged release tablets
sanofi-aventis ireland limited - alfuzosin hydrochloride - tablet prolonged release - 10 milligram